Hypothyroidism

Pollie is Redefining Personalized Care for Complex Female Health Issues and Announces Expansion of Services

Retrieved on:

수요일, 6월 21, 2023

Endometriosis, Insulin resistance, Woman, Infertility, Health, Diabetes, Hashimoto's thyroiditis, Patient, PCOS, Polycystic ovary syndrome, Hypothyroidism, Female, Nursing, Birth control

DENVER, June 21, 2023 /PRNewswire/ -- Pollie, a digital health company providing personalized care for female health issues, today announced its expansion to serve all women with chronic hormone, autoimmune, metabolic and gastrointestinal conditions.

Key Points:

The Pollie app, initially designed to provide personalized care plans for women with polycystic ovary syndrome, is now expanding to help members manage other complex female conditions with its effective approach.
DENVER, June 21, 2023 /PRNewswire/ -- Pollie, a digital health company providing personalized care for female health issues, today announced its expansion to serve all women with chronic hormone, autoimmune, metabolic and gastrointestinal conditions.
"Over time, we found that our approach wasn't just improving members' PCOS, but also having a remarkable positive impact on their metabolic health, thyroid health and overall health."
With the expansion, Pollie is also lowering the price of its flagship Program membership from $89.99/month to $65.99/month.

Xeris Biopharma Announces First Participant Dosed in a Phase 2 Clinical Study of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) in Patients With Hypothyroidism

Retrieved on:

수요일, 6월 21, 2023

Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, TSH, Medical Affairs Bureau, Prescription, Doctor of Pharmacy, Safety, Patient, Hypothyroidism, Pharmaceutical industry

“Oral levothyroxine is one of the most prescribed medicines in the United States, generating more than 100 million prescriptions per year.

Key Points:

“Oral levothyroxine is one of the most prescribed medicines in the United States, generating more than 100 million prescriptions per year.
However, many patients experience one or more challenges associated with the oral therapy.
“We are excited to have dosed the first participant in our Phase 2 dose-finding study of XP-8121 and are actively recruiting additional participants that meet the eligibility criteria.
This study includes the following periods: Screening, Titration Period (2 to 8 weeks), and Maintenance Period (4 weeks).

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Retrieved on:

목요일, 5월 25, 2023

Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Senior, Hepatocellular carcinoma, Pharming, Sunitinib, Survival, Everolimus, RECIST, Head, DO, Cancer, Patient, Stomatitis, Risk, NYSE, Fatigue, Texas Oncology, Diarrhea, Pembrolizumab, FACP, MRK, Research, Lung cancer, Merck & Co., Hypertension, LEAP, HIV disease progression rates, IMDC, Esophageal cancer, Memorial Sloan Kettering Cancer Center, PD-1, Abstract, Death, Safety, Lenvatinib, Overalls, Multimedia, PFS, CR, Stomach, ORR, Acral lentiginous melanoma, IRC, Progression-free survival, RCC, CI, OS, Drug, Trae tha Truth, MSKCC, Hypothyroidism, EDT, ASCO, American Society of Clinical Oncology, Cancer Treatment Centers of America, Physician, Quality of life (healthcare), Annual general meeting, Nausea, Interpretation, Society, Pharmaceutical industry, Dietary supplement, Merck, EU, Eisai

After four years of follow-up, KEYTRUDA plus LENVIMA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).

Key Points:

After four years of follow-up, KEYTRUDA plus LENVIMA maintained a clinically meaningful OS benefit versus sunitinib, reducing the risk of death by 21% (HR=0.79 [95% CI, 0.63-0.99]).
The 24- and 36-month estimated OS rates were 80.4% and 66.4% for KEYTRUDA plus LENVIMA versus 69.6% and 60.2% for sunitinib, respectively.
Results from the final pre-specified OS analysis were consistent with the superior results versus sunitinib from the primary OS analysis of the CLEAR/KEYNOTE-581 trial.
Grade ≥3 treatment-related adverse events (TRAE) occurred in 74.1% of patients who received KEYTRUDA plus LENVIMA versus 60.3% of patients who received sunitinib.

IBSA’s Initiatives Focused on the Patients’ Experience and a Greater Knowledge of Thyroid Dysfunctions

Retrieved on:

목요일, 5월 25, 2023

Thyroid dysfunctions are quite common: it is estimated that over 1.5 billion people worldwide are at risk of thyroid disorders, and that hypothyroidism alone affects 5% of the world’s population1, with a greater incidence among women.

Key Points:

Thyroid dysfunctions are quite common: it is estimated that over 1.5 billion people worldwide are at risk of thyroid disorders, and that hypothyroidism alone affects 5% of the world’s population1, with a greater incidence among women.
Because symptoms are often non-specific, many people living with a thyroid disorder are currently undiagnosed and they can spend many years struggling with a poor quality of life before getting a diagnosis.
To raise awareness of these conditions and support patients in their daily management, IBSA launches “Feel Thyroid”, the international campaign aimed at raise awareness on hypothyroidism in particular.
The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites.

Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

Retrieved on:

금요일, 5월 12, 2023

JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol.

Key Points:

JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol.
The results provide further support for the use of dual immunotherapy in patients with advanced solid tumors.
The CTLA-4 antibody has a shorter elimination half-life in vivo, with a shorter exposure for CTLA-4 antibodies in a dosing cycle.
This study provides strong support for further clinical research of QL1706, which is expected to become a new approach of dual immunotherapy.

Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

Retrieved on:

목요일, 5월 11, 2023

The results provide further support for the use of dual immunotherapy in patients with advanced solid tumors.

Key Points:

The results provide further support for the use of dual immunotherapy in patients with advanced solid tumors.
The CTLA-4 antibody has a shorter elimination half-life in vivo, with a shorter exposure for CTLA-4 antibodies in a dosing cycle.
QL1706 therefore not only has a synergistic mechanism to block PD-1 and CTLA-4, but also reduces the toxicity of CTLA-4 antibodies.
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.

Danish Startups Pursue US Expansion Opportunities Through TMC BioBridge

Retrieved on:

수요일, 5월 3, 2023

HOUSTON and COPENHAGEN, Denmark, May 3, 2023 /PRNewswire/ -- Texas Medical Center (TMC) and the BioInnovation Institute (BII) announced today that three start-ups from BII will join a customized accelerator program tailored for helping startups build their US go-to-market strategy. The specialized accelerator is modeled and builds off the success of the TMC Innovation (TMCi) Health Tech Accelerator program. The Denmark Biobridge between the TMC and the Ministry of Foreign Affairs of Denmark was signed in 2019.

Key Points:

The specialized accelerator is modeled and builds off the success of the TMC Innovation (TMCi) Health Tech Accelerator program.
The Denmark Biobridge between the TMC and the Ministry of Foreign Affairs of Denmark was signed in 2019.
TMC Innovation Factory offers a strategic entry point with training, access, and support for these small and medium-sized enterprises seeking to learn, expand and commercialize in the US market.
The startups' areas of focus range from surgical devices to AI-enabled risk stratification and hospital efficiency.

Danish Startups Pursue US Expansion Opportunities Through TMC BioBridge

Retrieved on:

수요일, 5월 3, 2023

HOUSTON and COPENHAGEN, Denmark, May 3, 2023 /PRNewswire/ -- Texas Medical Center (TMC) and the BioInnovation Institute (BII) announced today that three start-ups from BII will join a customized accelerator program tailored for helping startups build their US go-to-market strategy. The specialized accelerator is modeled and builds off the success of the TMC Innovation (TMCi) Health Tech Accelerator program. The Denmark Biobridge between the TMC and the Ministry of Foreign Affairs of Denmark was signed in 2019.

Key Points:

The specialized accelerator is modeled and builds off the success of the TMC Innovation (TMCi) Health Tech Accelerator program.
The Denmark Biobridge between the TMC and the Ministry of Foreign Affairs of Denmark was signed in 2019.
TMC Innovation Factory offers a strategic entry point with training, access, and support for these small and medium-sized enterprises seeking to learn, expand and commercialize in the US market.
The startups' areas of focus range from surgical devices to AI-enabled risk stratification and hospital efficiency.

EQS-News: Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications

Retrieved on:

수요일, 5월 3, 2023

Tissue, FSE, PSH, Type 1 diabetes, Research, Hypothyroidism, AstraZeneca, Protein, Cell, TSX, Haemophilia, Environment, Pharmaceutical industry

LONDON, Ontario – May 3, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells.

Key Points:

LONDON, Ontario – May 3, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells.
“Sernova has developed a novel cell therapy approach for the potential treatment of insulin-dependent diabetes, hypothyroidism and hemophilia A,” said Dr. Philip Toleikis, President and Chief Executive Officer of Sernova.
Under the terms of the collaboration, AstraZeneca will lead and completely fund the development of the cell technologies and pre-clinical activities in conjunction with Sernova.
The preclinical research outcomes will determine the feasibility of potential therapeutic applications and subsequent product development activities between the two companies.

Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications

Retrieved on:

수요일, 5월 3, 2023

Tissue, FSE, PSH, Type 1 diabetes, Research, Hypothyroidism, AstraZeneca, Protein, Cell, TSX, Haemophilia, Environment, Pharmaceutical industry

LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells.

Key Points:

LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells.
“Sernova has developed a novel cell therapy approach for the potential treatment of insulin-dependent diabetes, hypothyroidism and hemophilia A,” said Dr. Philip Toleikis, President and Chief Executive Officer of Sernova.
Under the terms of the collaboration, AstraZeneca will lead and completely fund the development of the cell technologies and pre-clinical activities in conjunction with Sernova.
The preclinical research outcomes will determine the feasibility of potential therapeutic applications and subsequent product development activities between the two companies.